References
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://www.ncbi.nlm.nih.gov/pubmed28055103. DOI: 10.3322/caac.21387
- Mendenhall WM, Amdur RJ, Grobmyer SR, George TJ, Werning JW, Hochwald SN, et al. Adjuvant radiotherapy for cutaneous melanoma. Cancer. 2008;112(6):1189–1196. https://www.ncbi.nlm.nih.gov/pubmed/18260153. DOI: 10.1002/cncr.23306
- Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys. 2006;66(4):1051–1055. https://www.ncbi.nlm.nih.gov/pubmed/16973303. DOI: 10.1016/j.ijrobp.2006.05.056
- Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351(10):998–1012. https://www.ncbi.nlm.nih.gov/pubmed/15342808. DOI: 10.1056/NEJMra041245
- Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C-h, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. JCO. 1999;17(3):976–983. https://www.ncbi.nlm.nih.gov/pubmed/10071292. DOI: 10.1200/JCO.1999.17.3.976
- Hanke CW, Wolf RL, Hochman SA, O'Brian JJ. Chemosurgical reports: perineural spread of basal-cell carcinoma. J Dermatol Surg Oncol. 1983;9(9):742–747. https://www.ncbi.nlm.nih.gov/pubmed/6886188.
- Feasel AM, Brown TJ, Bogle MA, Tschen JA, Nelson BR. Perineural invasion of cutaneous malignancies. Dermatol Surg. 2001;27(6):531–542. https://www.ncbi.nlm.nih.gov/pubmed/11442588.
- Birkby CS, Whitaker DC. Management considerations for cutaneous neurophilic tumors. J Dermatol Surg Oncol. 1988;14(7):731–737. https://www.ncbi.nlm.nih.gov/pubmed/3392314.
- Goepfert H, Dichtel WJ, Medina JE, Lindberg RD, Luna MD. Perineural invasion in squamous cell skin carcinoma of the head and neck. Am J Surg. 1984;148(4):542–547. https://www.ncbi.nlm.nih.gov/pubmed/6486325.
- Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Malyapa RS, Villaret DB, et al. Skin cancer of the head and neck with perineural invasion. Am J Clin Oncol. . 2007;30(1):93–96. https://www.ncbi.nlm.nih.gov/pubmed/17278901. DOI: 10.1097/01.coc.0000251224.16075.60
- Jackson JE, Dickie GJ, Wiltshire KL, Keller J, Tripcony L, Poulsen MG, et al. Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: toward a risk-adapted treatment approach. Head Neck. 2009;31(5):604–610. https://www.ncbi.nlm.nih.gov/pubmed/19132719. DOI: 10.1002/hed.20991
- Garcia-Serra A, Hinerman RW, Mendenhall WM, Amdur RJ, Morris CG, Williams LS, et al. Carcinoma of the skin with perineural invasion. Head Neck. 2003;25(12):1027–1033. https://www.ncbi.nlm.nih.gov/pubmed/14648861. DOI: 10.1002/hed.10334
- Geist D, Garcia-Moliner M, Fitzek M, Cho H, Rogers G. Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg. 2008;34(12):1642–1651. https://www.ncbi.nlm.nih.gov/pubmed/19018830. DOI: 10.1111/j.1524-4725.2008.34341.x
- Balamucki CJ, Mancuso AA, Amdur RJ, Kirwan JM, Morris CG, Flowers FP, et al. Skin carcinoma of the head and neck with perineural invasion. Am J Otolaryngol. 2012;33(4):447–454. https://www.ncbi.nlm.nih.gov/pubmed/22185685. DOI: 10.1016/j.amjoto.2011.11.004
- Newlin HE, Morris CG, Amdur RJ, Mendenhall WM. Neurotropic melanoma of the head and neck with clinical perineural invasion. Am J Clin Oncol. 2005;28(4):399–402. https://www.ncbi.nlm.nih.gov/pubmed/16062083.
- Edge S, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. New York (NY): Springer; 2011.
- Mendenhall WM, Amdur RJ, Morris CG, Kirwan J, Shaw C, Dziegielewski PT. Adjuvant postoperative radiotherapy for cutaneous melanoma. Acta Oncol. 2017;56(3):495–496. https://www.ncbi.nlm.nih.gov/pubmed/28256960. DOI: 10.1080/0284186X.2017.1295168
- Ang KK, Byers RM, Peters LJ, Maor MH, Wendt CD, Morrison WH, et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch Otolaryngol Head Neck Surg. 1990;116(2):169–172. https://www.ncbi.nlm.nih.gov/pubmed/2297407.
- NCI. Common Terminology Criteria for Adverse Events, version 4.0. 2010. [2017 May 31]; Available from: https://evs.nci.nih.gov/ftp1/CTCAE/About.html.
- Ivan D, Prieto VG. An update on reporting histopathologic prognostic factors in melanoma. Arch Pathol Lab Med. 2011;135:825–829. https://www.ncbi.nlm.nih.gov/pubmed/21732769. DOI: 10.1043/2010-0229-RAR.1
- Chen LL, Jaimes N, Barker CA, Busam KJ, Marghoob AA. Desmoplastic melanoma: a review. J Am Acad Dermatol. 2013;68(5):825–833. https://www.ncbi.nlm.nih.gov/pubmed/23267722. DOI: 10.1016/j.jaad.2012.10.041
- Frydenlund N, Mahalingam M. Desmoplastic melanoma, neurotropism, and neurotrophin receptors-what we know and what we do not. Adv Anat Pathol. 2015;22(4):227–241. https://www.ncbi.nlm.nih.gov/pubmed/26050260. DOI: 10.1097/PAP.0000000000000076
- Iwamoto S, Odland PB, Piepkorn M, Bothwell M. Evidence that the p75 neurotrophin receptor mediates perineural spread of desmoplastic melanoma. J Am Acad Dermatol. 1996;35(5):725–731. https://www.ncbi.nlm.nih.gov/pubmed/8912568.
- Iwamoto S, Burrows RC, Agoff SN, Piepkorn M, Bothwell M, Schmidt R. The p75 neurotrophin receptor, relative to other Schwann cell and melanoma markers, is abundantly expressed in spindled melanomas. Am J Dermatopathol. 2001;23(4):288–294. https://www.ncbi.nlm.nih.gov/pubmed/11481518.
- Chan MM, Tahan SR. Low-affinity nerve growth factor receptor (P75 NGFR) as a marker of perineural invasion in malignant melanomas. J Cutan Pathol. 2010;37(3):336–343. https://www.ncbi.nlm.nih.gov/pubmed/19615036. DOI: 10.1111/j.1600-0560.2009.01349.x
- Reed JA, Finnerty B, Albino AP. Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression. Am J Pathol. 1999;155(2):549–555. https://www.ncbi.nlm.nih.gov/pubmed/10433947. DOI: 10.1016/S0002-9440(10)65150-4
- Perosio PM, Brooks JJ. Expression of nerve growth factor receptor in paraffin-embedded soft tissue tumors. Am J Pathol. 1988;132(1):152–160. https://www.ncbi.nlm.nih.gov/pubmed/2456020.
- Lazova R, Tantcheva-Poor I, Sigal AC. P75 nerve growth factor receptor staining is superior to S100 in identifying spindle cell and desmoplastic melanoma. J Am Acad Dermatol. 2010;63(5):852–858. https://www.ncbi.nlm.nih.gov/pubmed/20950740. DOI: 10.1016/j.jaad.2009.11.688